TransCode Therapeutics, Inc. (RNAZ)
Develops RNA-based cancer treatments to stop tumor growth and boost immune response.
$4.73-0.13%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-58.9%
The outlook
TransCode Therapeutics trades at $4.73, well below both its 50- and 200-day moving averages and sitting near its 52-week low. Analyst coverage appears minimal, making consensus ratings unavailable. The overall data picture leans decidedly bearish based on current price positioning and trend weakness.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range5% of the way from its 52-week low to high
Market cap
$4.5M
52-wk high
$20.99
52-wk low
$3.82
50-day avg
$6.42
200-day avg
$8.69
Trailing P/E
—